Cathepsin S promotes pulmonary arterial hypertension through the disruption of PPARγ, leading to pulmonary vascular remodeling, which can be suppressed by a selective Cat S inhibitor.
Does Cathepsin S inhibition prevent pulmonary vascular remodeling in pulmonary arterial hypertension models?
Cathepsin S promotes pulmonary arterial hypertension through PPARγ disruption, and its inhibition suppresses pulmonary vascular remodeling in preclinical models.
Cysteine cathepsin proteases play critical roles in cardiovascular disease progression and are implicated in extracellular matrix (ECM) degradation. Patients with pulmonary arterial hypertension (PAH) exhibit increased elastase production by pulmonary arterial smooth muscle cells (PASMCs), which is related to the degradation of elastic fibers and pulmonary vascular remodeling. However, the mechanism by which cathepsins regulate the ECM and PASMC proliferation in PAH remains unclear. We hypothesized that cathepsin proteases in PASMCs promote the development of PAH. Here, we show overexpression of cathepsin S (Cat S) and degradation of elastic laminae in the lungs of patients with idiopathic PAH and in the PASMCs of monocrotaline-induced PAH model (MCT-PAH) rats. In addition, pulmonary hypertension can be treated in MCT-PAH rats by administering a selective Cat S inhibitor, Millipore-219393, which stimulates peroxisome proliferator-activated receptor-γ (PPARγ) to inhibit the expression of Cat S, thus suppressing the proliferation and migration of MCT-PAH PASMCs. We then reduced Cat S or PPARγ expression by using small interfering RNA in human PASMCs to demonstrate a mechanistic link between Cat S signaling and PPARγ protein, and the results suggest that PPARγ is upstream of Cat S signaling. In conclusion, the activity of Cat S in pulmonary vascular remodeling and degradation of elastin fibers through the disruption of PPARγ is pathophysiologically significant in PAH.
Chang et al. (Wed,) conducted a other in Pulmonary arterial hypertension. Cathepsin S inhibitor (Millipore-219393) was evaluated on Pulmonary vascular remodeling and degradation of elastin fibers. Cathepsin S promotes pulmonary arterial hypertension through the disruption of PPARγ, leading to pulmonary vascular remodeling, which can be suppressed by a selective Cat S inhibitor.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: